Testing a new immune drug for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This Phase 1 study tests denikitug (GS-1811) alone or with zimberelimab in adults with advanced solid tumors. It’s looking mainly at safety and how the treatment works in people whose cancer has already been treated—or is not treatable with standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid tumor cancer that’s been proven by a pathology test (biopsy or cells).
- Your cancer has either been treated before and stopped working, or you can’t take the standard treatments that usually help.
- Your scans must show measurable cancer spots (measurable disease).
- Your general strength/ability to do daily activities must be in a certain range (ECOG 0–2, depending on the group).
- Your organs must work well enough for study treatment (blood tests/liver/kidneys are acceptable).
- You must be able to provide tumor tissue before starting, and in some groups also have an extra biopsy during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
This early-phase trial tests NB002, a new immune-targeting medicine, to find safe doses and see how well it can treat advanced or metastatic solid cancers that have not responded to standard treatments. It may help by strengthening the immune system’s ability to fight the tumor.
This Phase 1/2 trial studies ZGGS18, a new medicine, in people with advanced solid tumors that either no longer respond to standard treatment or for whom standard treatment isn’t an option. The goal is to see how the drug works and what side effects it causes.
This Phase 1 trial studies ZG0895.HCl, a new experimental treatment, in people with advanced solid cancers. It’s mainly to check safety and how the body responds, and it may help by shrinking or controlling tumors if the drug works.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.